Skip to content
Open access · OA via OpenAlex

RDNA-07. INCREASING EXTENT OF ABLATION – A SENOLYTIC APPROACH TO PROMOTE APOPTOSIS OF LATENT GLIOBLASTOMA FOLLOWING CHEMORADIATION

Masum Rahman, Ian Olson, Zhi Tang, Karishma R. Rajani, Lucas P. Carlstrom, Terry C. Burns

Neuro-Oncology · 2019

Abstract

Abstract BACKGROUND Despite best current therapies, median survival for glioblastoma remains little more than a year. There remains an urgent need for improved treatment strategies. Current therapies, including radiation and temozolomide, are known to induce senescence(definition) in tumor cells. Advances in aging research have identified drugs with “senolytic” properties to kill senescent cells. This work tests the hypothesis that induction of senescence pathways following radiation can provide a window of opportunity to eliminate residual glioblastoma cells using drugs that block senescent cell-associated pathways (SCAPs). METHODS Human glioblastoma cells were radiated with 10, 15, or 20 Gy and maintained in culture for 3 to 4 weeks to facilitate maturation of a senescent phenotype. Given existence of multiple SCAPs, we evaluated the IC50 for several senolytic candidates including Dasatinib, Quercetin, Fisetin, AMG-232, Onalespib, A1331852, and Navitoclax in radiated vs non-radiated cells. RESULTS Among these, the Bcl-XL inhibitors A1331852 and Navitoclax both selectively killed multiple lines of radiated, senescent tumor cells at lower concentrations as compared to unirradiated, non-senescent tumor cells. Across multiple GBM cell line, the average IC50 for senescent cells was 12.88 nM (95%CI= 9.068–18.58 nM), as compared to the IC50 of non-senescent cells of 103.2 nM (95%CI= 74.24–143.9 nM; p< 0.005). Such differential sensitivity to Bcl-XL inhibition after radiation was not observed in the non-GBM control cells evaluated to date. CONCLUSION Our findings suggest that blocking the anti-apoptotic pathway Bcl-XL in GBM cells rendered at least transiently senescent following radiation may provide an avenue to selectively ablate residual glioblastoma cells following radiation. Our data provide proof of principle that senolytic therapy may represent a previously untapped window of opportunity to increase extent of tumor ablation following completion of standard cytotoxic therapies.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1093/neuonc/noz175.867
Canonical
link ↗
Fetched
2026-10-08 MST

Cite this

APA
Rahman, M., Olson, I., Tang, Z., Rajani, K.R., Carlstrom, L.P., &amp; Burns, T.C. (2019). RDNA-07. INCREASING EXTENT OF ABLATION – A SENOLYTIC APPROACH TO PROMOTE APOPTOSIS OF LATENT GLIOBLASTOMA FOLLOWING CHEMORADIATION. <em>Neuro-Oncology</em>. https://doi.org/10.1093/neuonc/noz175.867
Vancouver
Rahman M, Olson I, Tang Z, Rajani KR, Carlstrom LP, Burns TC. RDNA-07. INCREASING EXTENT OF ABLATION – A SENOLYTIC APPROACH TO PROMOTE APOPTOSIS OF LATENT GLIOBLASTOMA FOLLOWING CHEMORADIATION. Neuro-Oncology. 2019. doi:10.1093/neuonc/noz175.867.
BibTeX
@article{masum2019RDNAIN, title = {RDNA-07. INCREASING EXTENT OF ABLATION – A SENOLYTIC APPROACH TO PROMOTE APOPTOSIS OF LATENT GLIOBLASTOMA FOLLOWING CHEMORADIATION}, author = {Masum Rahman and Ian Olson and Zhi Tang and Karishma R. Rajani and Lucas P. Carlstrom and Terry C. Burns}, journal = {Neuro-Oncology}, year = {2019}, doi = {10.1093/neuonc/noz175.867}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings